These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 28689443)

  • 1. Does having a gastrectomy delay time to feeding and prolong hospital stay in patients undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy?
    Shannon NB; Tan GHC; Chia CS; Soo KC; Teo MC
    Int J Hyperthermia; 2018 Aug; 34(5):518-523. PubMed ID: 28689443
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Perioperative Morbidity of Gastrectomy During CRS-HIPEC: An ACS-NSQIP Analysis.
    Paredes AZ; Guzman-Pruneda FA; Abdel-Misih S; Hays J; Dillhoff ME; Pawlik TM; Cloyd JM
    J Surg Res; 2019 Sep; 241():31-39. PubMed ID: 31004870
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enterocutaneous fistula in patients with peritoneal malignancy following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: Incidence, management and outcomes.
    Valle SJ; Alzahrani N; Alzahrani S; Traiki TB; Liauw W; Morris DL
    Surg Oncol; 2016 Sep; 25(3):315-20. PubMed ID: 27566038
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Repeated cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with recurrent peritoneal carcinomatosis.
    Vassos N; Förtsch T; Aladashvili A; Hohenberger W; Croner RS
    World J Surg Oncol; 2016 Feb; 14(1):42. PubMed ID: 26912149
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ninety-day post-operative morbidity and mortality using the National Cancer Institute's common terminology criteria for adverse events better describe post-operative outcome after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
    Alyami M; Kim BJ; Villeneuve L; Vaudoyer D; Képénékian V; Bakrin N; Gilly FN; Cotte E; Glehen O; Passot G
    Int J Hyperthermia; 2018 Aug; 34(5):532-537. PubMed ID: 28838265
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cytoreductive Surgery and HIPEC in an Enhanced Recovery After Surgery Program: A Feasibility Study.
    Lu PW; Fields AC; Shabat G; Bleday R; Goldberg JE; Irani J; Stopfkuchen-Evans M; Melnitchouk N
    J Surg Res; 2020 Mar; 247():59-65. PubMed ID: 31767280
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Extreme cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: Outcomes from a single tertiary center.
    Berger Y; Aycart S; Mandeli JP; Heskel M; Sarpel U; Labow DM
    Surg Oncol; 2015 Sep; 24(3):264-9. PubMed ID: 26143715
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increased Incidence of Central Venous Catheter-Related Infection in Patients Undergoing Cytoreductive Surgery and Hyperthermic Intra-Peritoneal Chemotherapy.
    Waters PS; Smith AW; Fitzgerald E; Khan F; Moran BJ; Shields CJ; Lynch BL; O'Loughlin C; Lynch M; Mulsow J
    Surg Infect (Larchmt); 2019 Sep; 20(6):465-471. PubMed ID: 31013189
    [No Abstract]   [Full Text] [Related]  

  • 9. Significance of diabetes on morbidity and mortality following cytoreductive surgery with hyperthermic intraperitoneal chemotherapy.
    Randle RW; Ahmed S; Levine EA; Fino NF; Swett KR; Stewart JH; Shen P; Votanopoulos KI
    J Surg Oncol; 2015 May; 111(6):740-5. PubMed ID: 25556634
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Delayed presentation of major complications in patients undergoing cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy following hospital discharge.
    Bhagwandin SB; Naffouje S; Salti G
    J Surg Oncol; 2015 Mar; 111(3):324-7. PubMed ID: 25557653
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy with lobaplatin and docetaxel improves survival for patients with peritoneal carcinomatosis from abdominal and pelvic malignancies.
    Wu HT; Yang XJ; Huang CQ; Sun JH; Ji ZH; Peng KW; Zhang Q; Li Y
    World J Surg Oncol; 2016 Sep; 14(1):246. PubMed ID: 27633880
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predictors of progression in high-grade appendiceal or colorectal peritoneal carcinomatosis after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
    Baumgartner JM; Tobin L; Heavey SF; Kelly KJ; Roeland EJ; Lowy AM
    Ann Surg Oncol; 2015 May; 22(5):1716-21. PubMed ID: 25145504
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Does early post-operative intraperitoneal chemotherapy (EPIC) for patients treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) make a difference?
    Tan GH; Ong WS; Chia CS; Tham CK; Soo KC; Teo MC
    Int J Hyperthermia; 2016 May; 32(3):281-8. PubMed ID: 26862667
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Novel Tool for Predicting Major Complications After Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy.
    Baumgartner JM; Kwong TG; Ma GL; Messer K; Kelly KJ; Lowy AM
    Ann Surg Oncol; 2016 May; 23(5):1609-17. PubMed ID: 26678406
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy in Elderly Patients: Complete Cytoreduction Is Feasible and Crucial for Improved Survival Despite High Carcinomatosis Index.
    Naffouje SA; Salti GI
    Anticancer Res; 2018 Jan; 38(1):441-448. PubMed ID: 29277807
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Factors Associated with Readmission After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Carcinomatosis.
    Martin AS; Abbott DE; Hanseman D; Sussman JE; Kenkel A; Greiwe P; Saeed N; Ahmad SH; Sussman JJ; Ahmad SA
    Ann Surg Oncol; 2016 Jun; 23(6):1941-7. PubMed ID: 26842489
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cytoreduction with hyperthermic intraperitoneal chemotherapy: an appraisal of outcomes and cost at a newly established peritoneal malignancy program.
    Hinkle NM; MacDonald J; Sharpe JP; Dickson P; Deneve J; Munene G
    Am J Surg; 2016 Sep; 212(3):413-8. PubMed ID: 27086201
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Laparoscopic cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for perforated low-grade appendiceal mucinous neoplasms.
    Abudeeb H; Selvasekar CR; O'Dwyer ST; Chakrabarty B; Malcolmson L; Renehan AG; Wilson MS; Aziz O
    Surg Endosc; 2020 Dec; 34(12):5516-5521. PubMed ID: 31993814
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment-Related Mortality After Cytoreductive Surgery and HIPEC in Patients with Colorectal Peritoneal Carcinomatosis is Underestimated by Conventional Parameters.
    Simkens GA; van Oudheusden TR; Braam HJ; Luyer MD; Wiezer MJ; van Ramshorst B; Nienhuijs SW; de Hingh IH
    Ann Surg Oncol; 2016 Jan; 23(1):99-105. PubMed ID: 26148758
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Meta-analysis of prognostic factors for patients with colorectal peritoneal metastasis undergoing cytoreductive surgery and heated intraperitoneal chemotherapy.
    Hallam S; Tyler R; Price M; Beggs A; Youssef H
    BJS Open; 2019 Oct; 3(5):585-594. PubMed ID: 31592510
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.